ProMetic Life Sciences (OTCMKTS:PFSCF) & Vaxxinity (NASDAQ:VAXX) Head to Head Comparison

Volatility and Risk

Vaxxinity has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.

Institutional & Insider Ownership

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Vaxxinity and ProMetic Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%

Valuation & Earnings

This table compares Vaxxinity and ProMetic Life Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93 million	($0.45)	0.00
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A

Vaxxinity has higher earnings, but lower revenue than ProMetic Life Sciences.

Summary

Vaxxinity beats ProMetic Life Sciences on 6 of the 8 factors compared between the two stocks.

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.